Reiman T, Seeberger K, Taylor B J, Szczepek A J, Hanson J, Mant M J, Coupland R W, Belch A R, Pilarski L M
Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada.
Blood. 2001 Nov 1;98(9):2791-9. doi: 10.1182/blood.v98.9.2791.
Multiple myeloma (MM) is identified by unique immunoglobulin heavy chain (IgH) variable diversity joining region gene rearrangements, termed clonotypic, and an M protein termed the "clinical" isotype. Transcripts encoding clonotypic pre and postswitch IgH isotypes were identified in MM peripheral blood mononuclear cells (PBMCs), bone marrow (BM), and mobilized blood. For 29 patients, 38 BM, 17 mobilized blood, and 334 sequential PBMC samples were analyzed at diagnosis, before and after transplantation for 2 to 107 months. The clinical clonotypic isotype was readily detectable and persisted throughout treatment. Eighty-two percent of BM and 38% of PBMC samples also expressed nonclinical clonotypic isotypes. Clonotypic immunoglobulin M (IgM) was detectable in 68% of BM and 25% of PBMC samples. Nonclinical clonotypic isotypes were detected in 41% of mobilized blood samples, but clonotypic IgM was detected in only 12%. Patients with persistent clonotypic IgM expression had adverse prognostic features at diagnosis (lower hemoglobin, higher beta(2)-microglobulin) and higher numbers of BM plasma cells compared with patients with infrequent/absent clonotypic IgM. Patients with persistent clonotypic IgM expression had significantly poorer survival than patients with infrequent IgM expression (P <.0001). In a multivariate analysis, persistent clonotypic IgM expression in the blood correlated independently with poor survival (P =.01). In nonobese diabetic severe combined immunodeficiency mice, xenografted MM cells expressed clinical and nonclinical postswitch clonotypic isotypes. MM expressing clonotypic IgM engrafted both primary and secondary mice, indicating their persistence within the murine BM. This study demonstrates that MM clonotypic cells expressing preswitch transcripts are tied to disease burden and outcomes. Because MM pathology involves postswitch plasma cells, this raises the possibility that IgH isotype switching in MM may accompany worsening disease.
多发性骨髓瘤(MM)通过独特的免疫球蛋白重链(IgH)可变区多样性连接区基因重排(称为克隆型)和一种称为“临床”同种型的M蛋白来识别。在MM外周血单核细胞(PBMC)、骨髓(BM)和动员血中鉴定出编码克隆型转换前和转换后IgH同种型的转录本。对29例患者的38份骨髓、17份动员血和334份连续的PBMC样本在诊断时、移植前后2至107个月进行了分析。临床克隆型同种型易于检测到且在整个治疗过程中持续存在。82%的骨髓样本和38%的PBMC样本也表达非临床克隆型同种型。68%的骨髓样本和25%的PBMC样本中可检测到克隆型免疫球蛋白M(IgM)。41%的动员血样本中检测到非临床克隆型同种型,但仅12%的样本中检测到克隆型IgM。与克隆型IgM表达稀少/缺失的患者相比,持续表达克隆型IgM的患者在诊断时具有不良预后特征(血红蛋白较低、β2微球蛋白较高)且骨髓浆细胞数量较多。持续表达克隆型IgM的患者的生存率明显低于克隆型IgM表达稀少的患者(P<.0001)。在多变量分析中,血液中持续的克隆型IgM表达与不良生存率独立相关(P =.01)。在非肥胖糖尿病严重联合免疫缺陷小鼠中,异种移植的MM细胞表达临床和非临床转换后克隆型同种型。表达克隆型IgM的MM植入了初代和二代小鼠,表明它们在小鼠骨髓中持续存在。这项研究表明,表达转换前转录本的MM克隆型细胞与疾病负担和预后相关。由于MM病理学涉及转换后浆细胞,这增加了MM中IgH同种型转换可能伴随疾病恶化的可能性。